Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
The FDA approved expanded use of CASGEVY for patients ages 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first genetic therapy approved for children this young. This expansion adds approximately 5,500 eligible children in the U.S. to the addressable market, complementing the prior approval for ages 12+. Vertex has established over 75 authorized treatment centers in the U.S.
Key figures
- Drug Name
- CASGEVY (exagamglogene autotemcel)
- Eligible patients us
- 5500
- Treatment centers us
- 75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.